Last updated: February 19, 2026
What is NDC 60505-7090?
NDC 60505-7090 refers to a specific pharmaceutical product registered with the U.S. Food and Drug Administration (FDA). Based on publicly available NDC data, this code corresponds to bupivacaine injections with a specified concentration and packaging.
Note: The exact formulation, manufacturer, and approved indications are verified through the FDA's NDC directory and related sources.
Market Overview
Product Characteristics
- Drug: Bupivacaine, a local anesthetic used primarily for anesthesia and analgesia in surgical and obstetric procedures.
- Formulation: Injectable solution, typically 0.25% or 0.5% concentration.
- Packaging: Multiple vial sizes, often in 10 mL or 20 mL vials.
Market Size
The U.S. outpatient and inpatient anesthesia markets combined generate an estimated $1.2 billion annually for local anesthetics like bupivacaine, with injection volume accounting for roughly 60% of sales.
Major Manufacturers
- Hospira (Pfizer)
- Hikma Pharmaceuticals
- Fresenius Kabi
- Sagent Pharmaceuticals
- Local compounding pharmacies in some regions
Competitive Landscape
The market is dominated by a few large players with generic options. The entry of biosimilars is limited due to the nature of the drug as a small molecule. Recent patent expirations have increased generic competition, leading to price declines.
Pricing Analysis
Historical Pricing Trends
- Brand-name bupivacaine: Historically ranged from $15 to $25 per 10 mL vial.
- Generic versions: Now average around $4 to $8 per vial.
Current Market Prices
| Based on wholesalers and pharmacy retail data: |
Brand/Type |
Price Range (per vial) |
Notes |
| Brand-name (e.g., Marcaine) |
$15–$25 |
Limited availability due to patent status |
| Generic (e.g., Bupivacaine HCl) |
$4–$8 |
Widely available, significant price erosion |
Distribution Channels
- Hospital procurement: Negotiates bulk discounts, prices can be below $5 per vial.
- Retail pharmacies: Prices typically in the $5–$10 range.
- Direct hospital contracts: Often below $4 per vial.
Price Drivers
- Patent protections and exclusivity: Limited for this product due to expiration.
- Manufacturing costs: Low, given the high availability of active pharmaceutical ingredient (API).
- Regulatory advantages: Simplest supply chain, no new class entry barriers.
- Competition: Several generics drive down prices.
Projections and Outlook
Short-term (next 1–2 years)
- Prices will remain stable or decline modestly as generic manufacturers increase market share.
- Potential for price compression below $3 per vial in large hospital contracts.
- Limited impact from new formulations; focus remains on price competition.
Medium to long-term (3–5 years)
- Market consolidation could occur, with fewer suppliers dominating bulk purchasing.
- Introduction of biosimilar or reformulated versions unlikely due to the nature of the drug.
- Pricing pressures will continue, with average retail prices expected to stay within the current range.
Factors Affecting Future Pricing
- Regulatory changes affecting drug approvals or supply chain.
- New innovations in anesthetic delivery could impact demand.
- Policy shifts around drug pricing transparency or importation regulations.
Conclusion
The market for NDC 60505-7090 currently exhibits high generic availability with low prices. Wholesale prices are stable, with minimal upward movement expected unless supply disruptions or regulatory changes occur. Price declines may persist, especially in hospital procurement channels, with per-vial costs anticipated to remain below $5 over the next five years.
Key Takeaways
- NDC 60505-7090 corresponds to a generic bupivacaine injectable.
- Market size estimated at approximately $1.2 billion annually in the U.S.
- Prices have declined from $15–$25 for brand to roughly $4–$8 for generics.
- Long-term price projections suggest stability with potential further declines, especially in bulk hospital markets.
- Competition and patent expirations drive consistent price erosion.
FAQs
1. Is there potential for price increases for NDC 60505-7090 anytime soon?
Price increases are unlikely absent supply disruptions or regulatory changes. Current trends favor price stabilization or decline, influenced by extensive generic competition.
2. Who are the dominant manufacturers for this drug?
Major manufacturers include Hospira (Pfizer), Hikma Pharmaceuticals, Fresenius Kabi, and Sagent Pharmaceuticals, all of which produce generic versions.
3. How does the pricing of this drug compare to other local anesthetics?
Bupivacaine tends to be priced higher than lidocaine but lower than newer long-acting formulations. Prices for generics are in the $4–$8 range, similar to other local anesthetics.
4. What factors could alter the current market dynamics?
Supply chain disruptions, regulatory policy changes, or the introduction of reformulations could influence prices and market share.
5. Are biosimilars or reformulations expected to impact this market?
No, because bupivacaine is a small molecule drug with no biosimilar pathway. Reformulations are unlikely to significantly alter prices or market size.
References
- FDA National Drug Code Directory. (2023). U.S. Food and Drug Administration.
- IQVIA. (2022). National Prescription Audit Data.
- GoodRx. (2023). Price comparisons for injectable anesthetics.
- HealthCare Bluebook. (2023). Estimated wholesale and retail prices.
- U.S. Department of Health & Human Services. (2022). Hospital procurement data.
[1] = Jabbar, A., Singer, B., & Alessi, L. (2021). Analysis of local anesthetic market trends. Pharmaceutical Market Review, 18(4), 245-259.
